Claims

1. Use of a mesenchymal stem cell in the manufacture of a medicament for the treatment, modulation, prophylaxis, and/or amelioration of an inflammatory and/or immune disorder, wherein the medicament is to be administered into the lymphatic system by intralymphatic injection.

2. The use of claim 1, wherein the disorder is selected from the group consisting of celiac disease, rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.

3. The use of claim 1, wherein said mesenchymal stem cell is an adipose derived mesenchymal stem cell.

4. The use of claim 1 or claim 2, wherein the medicament further comprises an antigen.

5. The use of any of claims 1 to 4, wherein the mesenchymal stem cell is to be administered to a lymphatic organ, optionally a peripheral lymphatic organ, optionally a lymph node, optionally an axillary or inguinal lymph node.

6. The use of any of claims 1 to 5, wherein said administration is carried out by means of a syringe, optionally further comprising the step of using a radiological, ultrasound or imaging device to monitor the location of an injection needle.